Results 61 to 70 of about 22,830 (226)

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Current Oncology, 2022
Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1), demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC), although approval is currently limited to the treatment of ALK ...
Balázs Jóri, Markus Falk, Iris Hövel, Peggy Weist, Markus Tiemann, Lukas C. Heukamp, Frank Griesinger   +6 more
doaj   +1 more source

Immunohistochemical Detection ofROS1Fusion [PDF]

American Journal of Clinical Pathology, 2016
Patients whose tumors harbor ROS1 translocation may benefit from targeted therapy. Detection of ROS1 rearrangement can be done by three methods: immunohistochemistry, fluorescence in situ hybridization, and molecular assays. Immunohistochemistry would be a cost-effective means to screen for ROS1 translocation, which is uncommon.ROS1 immunostain was ...
Yuhua, Su, Theodore, Goncalves, Dora, Dias-Santagata, Mai P, Hoang   +3 more
openaire   +2 more sources

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source

Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing

Molecular Oncology, 2020
ROS1 gene rearrangements have been reported in diverse cancer types including non‐small‐cell lung cancer (NSCLC), and with a notably higher prevalence in lung adenocarcinoma.
Meiying Cui, Yuchen Han, Pan Li, Jianying Zhang, Qiuxiang Ou, Xiaoling Tong, Ruiying Zhao, Nan Dong, Xue Wu, Wencai Li, Guozhong Jiang   +10 more
doaj   +1 more source

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020

JTO Clinical and Research Reports, 2020
ROS1 fusion–positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development.
Sai-Hong Ignatius Ou, MD PhD, Misako Nagasaka, MD   +1 more
doaj   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

LINC01605 Predicts the Poor Prognosis of Non‐Small Cell Lung Cancer and Promotes Chemotherapy Resistance by Regulating miR‐7111‐5p/ELK1

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Non‐small cell lung cancer (NSCLC) is characterized by high incidence, mortality, and poor patient prognosis, with chemotherapy resistance being a common challenge. This research intends to identify key molecules involved in NSCLC and elucidate the regulatory role of the LINC01605/miR‐7111‐5p/ELK1 axis in chemotherapy resistance. LINC01605 and
Fang Zhang, Zhi‐Liang Yang, Tian‐Tian Qin, Guo‐Jun Zhang, Xiang Li   +4 more
wiley   +1 more source

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives

, 2017
Giulio Rossi,1 Genny Jocollé,2 Antonia Conti,3 Marcello Tiseo,4 Federica Zito Marino,5,6 Giovanni Donati,7 Renato Franco,5,6 Francesca Bono,8 Francesca Barbisan,9 Francesco Facchinetti4,10 1Pathology Unit, 2Oncology Unit, Azienda USL Valle d’
Rossi G, Donati G., Facchinetti F., Marino F. Z., Franco R., Zito Marino F, Tiseo M, Jocolle G., Tiseo M., Barbisan F., Franco R, Rossi G., Conti A, Barbisan F, Bono F, Jocollé G, Conti A., Bono F., Donati G, Facchinetti F   +19 more
core   +1 more source

Clinical Significance of ROS1 Rearrangements in Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2013
Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in multiple malignancies, including non-small cell lung cancer (NSCLC).
Luting XU, Ruijing ZHAO, Zengjun DONG, Tienian ZHU   +3 more
doaj   +1 more source

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report

Thoracic Cancer, 2021
C‐ros oncogene 1 receptor tyrosine kinase (ROS1) rearrangement has been detected in patients with advanced non‐small cell lung cancer (NSCLC). Although ROS1 tyrosine kinase inhibitors (TKIs) provide a survival benefit for patients with ROS1‐rearranged ...
Chi‐Hao Wu, Po‐Lan Su, Che‐Wei Hsu, Chang‐Yao Chu, Chien‐Chung Lin   +4 more
doaj   +1 more source